Supporting Healing ♦ Teaching ♦ Research
The Hadassah University Medical Center Blood Bank, a special fundraising project of Hadassah International, dedicated its newly refurbished and expanded facility in October. “Our standards are very high and the working conditions should be the same,” related Dr. Yuval Weiss, Director of Hadassah Hospital-Ein Kerem. Thanks in part to Hadassah International, now they are!
I was born at Hadassah, I studied at Hadassah, my children and grandchildren were born at Hadassah, my family receives medical treatment at Hadassah, my daughter, Irit, is a nephrologist at Hadassah. Hadassah has been my home for the last 38 years--from my first year of medical school until now --with just a few brief exceptions. In 1997, moved by the Negev's pioneering spirit, I agreed to head the Soroka Medical Center in Beersheva. For the last 11 years I have proudly headed Hadassah.
A Phase IIa clinical trial with a medicine to treat ischemic stroke has begun at the Hadassah University Medical Center, based on the research of Prof. Abd Al-Roof Higazi, head of the Department of Clinical Biochemistry at Hadassah Hospital Ein-Kerem.
Although he severely severed the palm of his hand, Sa'ad El-Kikh, an artist from the village of Tsurif near Hebron, is able to draw and paint once again thanks to a special tool affixed to his hand by Hadassah University Medical Center physical therapists.
Dear Friends, Visitors to our campuses often comment on the astonishing number of names that appear in our Medical Center --on the walls and in the halls, at the entrances to the buildings, patient rooms, laboratories and research centers.
Last week we dedicated the expanded and refurbished home of the blood bank at Hadassah-Ein Kerem.
Dr. Kevin Tabb, a graduate of the Hadassah-Hebrew University School of Medicine, has been named the next President and Chief Executive Officer of Beth Israel Deaconess Medical Center (BIDMC), the teaching hospital of Harvard University (Cambridge, MA).
A clinical trial conducted at the Hadassah University Medical Center has revealed that BreathID, a new noninvasive device for the detection of hepato-cellular carcinoma, a type of liver cancer, achieved diagnostic results similar to CT Scans and MRIs. BreathID was developed by Exalenz Bioscience Ltd., whose Medical Director is Prof. Yaron Ilan, Director of Hadassah’s Department of Internal Medicine A .
BreathID, a noninvasive early diagnosis device for acute liver failure developed at the Hadassah University Medical Center, has obtained a United States Food and Drug Administration (FDA) Humanitarian Device Exemption, which provides a fast-track toward approval. Prof. Yaron Ilan, Director of Hadassah’s Department of Internal Medicine A, is Medical Director of BreathID’s developer, Exalenz Bioscience Ltd., a startup company of Hadasit, Hadassah’s technology transfer arm.
Hope for a future cure of insulin-dependent (type 1) diabetes received a boost from the research findings of a multi-year project led by Prof. Yuval Dor of Hebrew University’s Institute for Medical Research Israel-Canada with Hadassah University Medical Center’s co-lead author Prof. Benjamin Glaser and his research team, who identified the key signal that initiates production of insulin-producing beta cells in the pancreas.